Over 75% of patients admitted to hospital with COVID-19 have abnormal patient-reported
outcome measures 3 months after symptom onset, with a third of patients reporting at least …

The long-term respiratory morbidity of COVID-19 remains unclear. We describe the clinical,
radiological and pulmonary function abnormalities that persist in previously hospitalised …

Fibrotic interstitial lung diseases (ILDs) are often challenging to diagnose and classify, but
an accurate diagnosis has significant implications for both treatment and prognosis. A subset …

… Author links open overlay panelAlyson W.WongMD a b … 42 WangW, Xu Y, Gao R, et al.
Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. …

The purpose of this study was to examine the physiological mechanisms of persistent dyspnoea
in COVID-19 survivors. Non-critical patients (n = 186) with varying degrees of COVID-19 …

Comorbidities are frequent and have been associated with poor quality of life, increased
hospitalizations, and mortality in patients with interstitial lung disease (ILD). However, it is …

Objectives The aim of this study was to compare respiratory and patient-reported outcome
measures (PROMs) between 3 and 6 months after symptom onset and to identify features that …

IPF is a progressive and fatal lung disease with increasing prevalence and a median survival
of 3-5 years following diagnosis. IPF is characterized by altered cellular composition and …

Methods We searched MEDLINE and EMBASE for all full-text articles published between
January 2000 and 2019 that provided a definition and/or diagnostic criteria for CPFE (protocol …

Pleuroparenchymal fibroelastosis (PPFE) is a progressive and frequently fatal interstitial
lung disease that involves the upper lobes. Although its cause remains unknown, the …